BMO Capital Maintains a “Buy” Rating on F5 Networks (FFIV) and $169.0000 Target; 2 Analysts Bullish Vical (VICL)

F5 Networks, Inc. (NASDAQ:FFIV) Logo

Among 2 analysts covering Vical (NASDAQ:VICL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vical had 8 analyst reports since July 19, 2016 according to SRatingsIntel. H.C. Wainwright maintained Vical Incorporated (NASDAQ:VICL) on Monday, January 22 with “Buy” rating. Rodman \u0026 Renshaw reinitiated the shares of VICL in report on Monday, June 12 with “Buy” rating. H.C. Wainwright maintained Vical Incorporated (NASDAQ:VICL) rating on Wednesday, August 9. H.C. Wainwright has “Buy” rating and $900 target. As per Friday, March 16, the company rating was maintained by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, November 21 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Monday, June 12. The rating was maintained by H.C. Wainwright on Thursday, February 1 with “Buy”. The company was reinitiated on Tuesday, July 19 by H.C. Wainwright. See Vical Incorporated (NASDAQ:VICL) latest ratings:

16/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Maintain
22/01/2018 Broker: H.C. Wainwright Rating: Buy Maintain
21/11/2017 Broker: H.C. Wainwright Rating: Buy Maintain

They currently have a $169.0000 price target on F5 Networks (NASDAQ:FFIV). BMO Capital’s target would suggest a potential upside of 7.60% from the company’s last stock price. This was revealed to clients and investors in an analyst report on Wednesday morning.

The stock increased 0.67% or $0.01 during the last trading session, reaching $1.51. About 27,751 shares traded. Vical Incorporated (NASDAQ:VICL) has declined 32.26% since April 26, 2017 and is downtrending. It has underperformed by 43.81% the S&P500.

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company has market cap of $32.94 million. It is developing various DNA vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. It currently has negative earnings. The firm also engages in contract manufacturing of plasmid investigational products for various clients.

The stock decreased 0.04% or $0.07 during the last trading session, reaching $157.07. About 896,943 shares traded or 13.47% up from the average. F5 Networks, Inc. (NASDAQ:FFIV) has declined 1.06% since April 26, 2017 and is downtrending. It has underperformed by 12.61% the S&P500.

Among 37 analysts covering F5 Networks Inc. (NASDAQ:FFIV), 9 have Buy rating, 1 Sell and 27 Hold. Therefore 24% are positive. F5 Networks Inc. has $168 highest and $90.0 lowest target. $130.26’s average target is -17.07% below currents $157.07 stock price. F5 Networks Inc. had 108 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was downgraded by Barclays Capital on Thursday, January 14 to “Underweight”. The company was maintained on Tuesday, December 22 by M Partners. The firm has “Hold” rating by Wunderlich given on Thursday, October 29. The firm earned “Hold” rating on Thursday, January 25 by Piper Jaffray. The firm earned “Equal-Weight” rating on Monday, October 9 by Morgan Stanley. BMO Capital Markets maintained the shares of FFIV in report on Thursday, January 25 with “Outperform” rating. The rating was upgraded by Citigroup on Thursday, January 21 to “Neutral”. As per Wednesday, November 30, the company rating was downgraded by Bernstein. KeyBanc Capital Markets maintained F5 Networks, Inc. (NASDAQ:FFIV) on Wednesday, October 11 with “Hold” rating. Drexel Hamilton maintained F5 Networks, Inc. (NASDAQ:FFIV) rating on Thursday, July 27. Drexel Hamilton has “Buy” rating and $16000 target.

Since February 1, 2018, it had 0 buys, and 9 selling transactions for $8.86 million activity. Shares for $396,540 were sold by Rogers Scot Frazier. Kearny Ryan C. sold $1.09 million worth of F5 Networks, Inc. (NASDAQ:FFIV) on Thursday, February 1. 3,457 shares were sold by Reinland Andrew, worth $499,183 on Friday, February 2. $289,014 worth of F5 Networks, Inc. (NASDAQ:FFIV) was sold by HIGGINSON ALAN. 25,000 F5 Networks, Inc. (NASDAQ:FFIV) shares with value of $3.60M were sold by MCADAM JOHN. DiLullo John D sold $542,378 worth of F5 Networks, Inc. (NASDAQ:FFIV) on Friday, February 2. $239,281 worth of F5 Networks, Inc. (NASDAQ:FFIV) shares were sold by Locoh-Donou Francois.

F5 Networks, Inc. develops, markets, and sells application delivery networking products that optimize the security, performance, and availability of network applications, servers, and storage systems. The company has market cap of $9.71 billion. The company??s primary application delivery technology is Traffic Management Operating System that enable company??s products to intercept, inspect, and act on the contents of traffic from virtually each type of Internet Protocol-enabled application. It has a 24.24 P/E ratio. It offers Local Traffic Manager, which provides intelligent load-balancing, traffic management, and application health checking; BIG-IP DNS that automatically directs users to the closest or best-performing physical, virtual, or cloud environment; Advanced Firewall Manager, a network firewall; and Application Security Manager, an Web application firewall that provides comprehensive, proactive, and application-layer protection against generalized and targeted attacks.

Investors sentiment is 0.84 in 2017 Q4. Its the same as in 2017Q3. It has no change, as 42 investors sold F5 Networks, Inc. shares while 174 reduced holdings. only 67 funds opened positions while 115 raised stakes. 55.68 million shares or 7.29% less from 60.06 million shares in 2017Q3 were reported. Rnc Mngmt Ltd reported 2,023 shares. Nomura Holdings stated it has 7,420 shares. Paloma Ptnrs Management owns 5,600 shares for 0.01% of their portfolio. Capital City Fl has invested 0.4% in F5 Networks, Inc. (NASDAQ:FFIV). Virtus Advisers Inc accumulated 2,083 shares. Laurion Mgmt L P stated it has 2,600 shares or 0% of all its holdings. Kornitzer Cap Mgmt Inc Ks invested 0.44% of its portfolio in F5 Networks, Inc. (NASDAQ:FFIV). Kentucky Retirement Sys Insurance Trust Fund reported 1,662 shares. Georgia-based Atlantic Trust Gru Lc has invested 0% in F5 Networks, Inc. (NASDAQ:FFIV). Aperio Grp Inc Ltd Llc holds 0.06% of its portfolio in F5 Networks, Inc. (NASDAQ:FFIV) for 87,826 shares. Pictet & Cie (Europe) Sa invested in 3,136 shares. Atria Investments Lc has 5,979 shares. Cwm Lc owns 42 shares. Lazard Asset Mgmt Ltd holds 0.05% or 189,156 shares in its portfolio. Kansas-based Cognios Capital Ltd Co has invested 0.15% in F5 Networks, Inc. (NASDAQ:FFIV).

F5 Networks, Inc. (NASDAQ:FFIV) Institutional Positions Chart